| Issue |
Section |
Title |
File |
| Vol 12, No 2 (2017) |
HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE |
TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA |
(Rus)
|
| Vol 13, No 3 (2018) |
HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE |
Follicular lymphoma: results of multicenter study of first-line therapy with bendamustine and rituximab, risk factors for adverse events (fl-rus-2013 protocol) |
(Rus)
|
| Vol 17, No 2 (2022) |
TREATMENT OF HEMATOLOGICAL MALIGNANCIES IN PATIENTS WITH COVID-19: PRO AND CONTRA |
Chemotherapy of hematological malignancies in patients with COVID-19 |
(Rus)
|
| Vol 18, No 4 (2023): Supplement |
Articles |
Basic therapeutic approaches to the management of hematology/oncology patients with new coronavirus infection (COVID-19) |
(Rus)
|
| Vol 18, No 4 (2023): Supplement |
Articles |
Treatment features of adult patients with acute myeloid leukemia during the COVID-19 pandemic |
(Rus)
|
| Vol 18, No 4 (2023): Supplement |
Articles |
Coronavirus infection after blood stem cell transplantation |
(Rus)
|
| Vol 18, No 4 (2023): Supplement |
Articles |
Clinical features and treatment strategy for patients with multiple myeloma during the COVID-19 pandemic |
(Rus)
|
| Vol 18, No 4 (2023): Supplement |
Articles |
Chronic lymphocytic leukemia in combination with COVID-19: clinical features and unfavorable prognosis factors |
(Rus)
|
| Vol 18, No 4 (2023): Supplement |
Articles |
COVID-19 in patients with acute leukemia: 3 years' experience of pandemic |
(Rus)
|
| Vol 18, No 4 (2023): Supplement |
Articles |
Treatment experience of coronavirus infection associated with SARS-CoV-2 in patients with acute myeloid leukemia in the older age group |
(Rus)
|
| Vol 18, No 4 (2023): Supplement |
Articles |
Prognostic model and risk factors for hospital mortality in patients with diffuse large B-cell lymphoma associated with coronavirus infection: a single-center cohort study |
(Rus)
|
| Vol 19, No 2 (2024) |
RARE AND COMPLEX CLINICAL SITUATIONS: DIAGNOSIS AND TREATMENT CHOICE |
Sinonasal diffuse large B-cell lymphoma: own clinical observation and literature review |
(Rus)
|
| Vol 19, No 2 (2024) |
CURRENT ASPECTS OF COVID-19 TREATMENT APPROACHES WITH SARS-COV-2 VIRUS PERSISTENCE IN ONCOLOGICAL/HEMATOLOGICAL PATIENTS |
Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2 |
(Rus)
|
| Vol 19, No 3 (2024) |
NEW DIRECTIONS, DIAGNOSTIC OPPORTUNITIES, AND TREATMENT ADVANCES |
Treatment efficiency in patients with acute myeloid leukemia from 2019 to 2023 according to the Moscow Cancer Registry |
(Rus)
|
| Vol 19, No 3 (2024) |
TREATMENT OF HEMATOLOGICAL MALIGNANCIES IN PATIENTS WITH COVID-19 |
COVID-19 in patients with acute lymphoblastic leukemia |
(Rus)
|
| Vol 19, No 4 (2024) |
HEMATOLOGIC MALIGNANCIES: TREATMENT |
Treatment of elderly patients with acute myeloid leukemia: personal experience |
(Rus)
|
| Vol 19, No 4 (2024) |
NEW DIRECTIONS, DIAGNOSTIC OPPORTUNITIES, AND TREATMENT ADVANCES |
Nivolumab-containing therapy in patients with newly diagnosed classical Hodgkin lymphoma: own clinical observations and literature review |
(Rus)
|
| Vol 19, No 4 (2024) |
NEW DIRECTIONS, DIAGNOSTIC OPPORTUNITIES, AND TREATMENT ADVANCES |
Personalized genotype-directed antitumor therapy for newly diagnosed diffuse large B-cell lymphoma: efficacy and toxicity of the R-CHOP-X protocol in a single-center, non-randomized, prospective clinical trial (first results) |
(Rus)
|
| Vol 20, No 3 (2025) |
HEMATOLOGIC MALIGNANCIES: TREATMENT |
Molecular phenotype of diffuse large B-cell lymphoma as a basis for a personalized treatment approach of elderly patients |
(Rus)
|
| Vol 20, No 3 (2025) |
SUPPORTIVE THERAPY ASPECTS |
The experience of a multidisciplinary team in maintaining fertility in oncohematological patients |
(Rus)
|
| Vol 20, No 4 (2025) |
HEMATOLOGIC MALIGNANCIES: TREATMENT |
Multiple myeloma: a retrospective analysis of clinical outcomes based on the patient registry of the Moscow City Clinical Hospital No. 52 (2022–2025) |
(Rus)
|
